Skip to main content
TipRanks
Go Ultimate75% OFF

Perspective Therapeutics (CATX) Stock Statistics & Valuation Metrics

1,694 Followers

Total Valuation

Perspective Therapeutics has a market cap or net worth of $94.20M. The enterprise value is $134.04M.

Market Cap
$94.20M
Enterprise Value
$134.04M

Share Statistics

Perspective Therapeutics has 120,758,810 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
120,758,810
Owned by Insiders
19.56%
Owned by Institutions
54.10%

Financial Efficiency

Perspective Therapeutics’s return on equity (ROE) is -0.50 and return on invested capital (ROIC) is -47.16%.

Return on Equity (ROE)
-0.50
Return on Assets (ROA)
-0.39
Return on Invested Capital (ROIC)
-47.16%
Return on Capital Employed (ROCE)
-0.48
Revenue Per Employee
0
Profits Per Employee
-624.98K
Employee Count
165
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Perspective Therapeutics is -0.63. Perspective Therapeutics’s PEG ratio is -0.04.

PE Ratio
-0.63
PS Ratio
532.23
PB Ratio
0.32
Price to FCF
-0.68
Price to Operating Cash Flow
-0.87
PEG Ratio
-0.04

Income Statement

In the last 12 months, Perspective Therapeutics had revenue of 0 and earned -103.12M in profits. Earnings per share was -1.40.

Revenue
0
Gross Profit
0
Operating Income
-113.56M
Pretax Income
-104.43M
Net Income
-103.12M
EBITDA
-100.80M
Earnings Per Share (EPS)
-1.40

Cash Flow

In the last 12 months, operating cash flow was -108.13M and capital expenditures -30.66M, giving a free cash flow of -138.79M billion.

Operating Cash Flow
-108.13M
Free Cash Flow
-138.79M
Free Cash Flow per Share
-1.15

Dividends & Yields

Perspective Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-147.33%
Earnings Yield
-130.48%

Stock Price Statistics

Beta
1.91
52-Week Price Change
-65.79%
50-Day Moving Average
2.06
200-Day Moving Average
3.41
Relative Strength Index (RSI)
27.58
Average Volume (3m)
2.69M

Important Dates

Perspective Therapeutics upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 09, 2026
Next Earnings Date
Apr 01, 2027
Ex-Dividend Date
―

Financial Position

Perspective Therapeutics as a current ratio of 5.17, with Debt / Equity ratio of 1.57%

Current Ratio
5.17
Quick Ratio
5.17
Debt to Market Cap
0.01
Net Debt to EBITDA
0.27
Interest Coverage Ratio
-302.03

Taxes

In the past 12 months, Perspective Therapeutics has paid -793.00K in taxes.

Income Tax
-793.00K
Effective Tax Rate
0.01

Enterprise Valuation

Perspective Therapeutics EV to EBITDA ratio is -0.47, with an EV/FCF ratio of -0.41.

EV to Sales
320.81
EV to EBITDA
-0.47
EV to Free Cash Flow
-0.41
EV to Operating Cash Flow
-0.53

Balance Sheet

Perspective Therapeutics has $201.69M in cash and marketable securities with $3.62M in debt, giving a net cash position of $198.07M billion.

Cash & Marketable Securities
$201.69M
Total Debt
$3.62M
Net Cash
$198.07M
Net Cash Per Share
$1.64
Tangible Book Value Per Share
$2.11

Margins

Gross margin is -536.16%, with operating margin of -74402.82%, and net profit margin of -69438.98%.

Gross Margin
-536.16%
Operating Margin
-74402.82%
Pretax Margin
-69887.57%
Net Profit Margin
-69438.98%
EBITDA Margin
-68378.53%
EBIT Margin
-70904.52%

Analyst Forecast

The average price target for Perspective Therapeutics is $7.89, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$7.89
Price Target Upside
911.40% Upside
Analyst Consensus
Strong Buy
Analyst Count
10
Revenue Growth Forecast
-79.53%
EPS Growth Forecast
14.45%

Scores

Smart Score
5
AI Score
47